- Details
- Andrew Armstrong joins Andrea Miyahira in discussing a retrospective analysis of the prospective multicenter PROPHECY trial of men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide seeking to develop a liquid biopsy using circulating tumor cells (CTCs) that they can associate with outcomes in men with mCRPC and ultimately apply that to a PSMA-tar...
|
- Details
- Andrea Miyahira and Akash Patnaik discuss a Clinical Cancer Research publication that explores a new approach to disrupt immuno metabolic pathways within an aggressive variant form of prostate cancer. Dr. Patnaik provides background on the current state of metastatic castrate-resistant prostate cancer and the biologic underpinnings of aggressive variant prostate cancer, focusing on the PTEN PI3-ki...
|
- Details
- Emmanuel Antonarakis joins Alicia Morgans in a conversation about the trial in progress multicenter, open-label, randomized phase 3 ECLIPSE trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer, previously treated with only one ARAT and are taxane-based chemo naive. The ECLIPSE trial is bei...
|
- Details
- Rahul Aggarwal joins Alica Morgans in conversation discussing a phase II study of patients with de novo small cell neuroendocrine prostate cancer, a high-risk group of patients with limited standard of care treatment options. The treatment was a combination immunotherapy trial, combining pembrolizumab, an immune checkpoint inhibitor, with BXCL 701, an investigational agent. The composite response...
|
- Details
- Alicia Morgans and Oliver Sartor discuss the latest developments and changes in the advanced prostate cancer landscape. Dr. Sartor mentions that novel hormones are used as first-line treatment in most cases and that the controversy around treating first-line metastatic CRPC is no longer relevant. He believes the evolution is going to continue with the novel hormones going earlier in different sett...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
- Details
- Alicia Morgans converses with Noel Clarke about the significance of biomarkers in castration-resistant prostate cancer. Dr. Clarke highlights the clinical importance of recognizing diversity among prostate cancer patients, particularly considering age and associated comorbidities. Noting that many patients, especially from socially deprived backgrounds, face challenges due to comorbidities, he und...
|
- Details
- Alicia Morgans and Cora Sternberg discuss the MAGNITUDE phase 3 trial which was pragmatically designed to test the benefit of the combination of niraparib + abiraterone acetate/prednisone for metastatic castration-resistant prostate cancer (mCRPC) in patients prospectively identified with and without alterations in genes associated with HRR using both tissue and blood-based approaches. Dr. Sternbe...
|
- Details
- In this conversation with Alicia Morgans, Simpa Salami discusses transcriptomic heterogeneity in multifocal prostate cancer and factors predisposing certain prostate cancer-focused to metastasis. Simpa Salami is a Prostate Cancer Foundation (PCF) Young Investigator Award recipient. Highlighting key takeaways from two research studies, Dr. Salami also shares how the PCF funding has supported this r...
|
- Details
- In this conversation with Charles Ryan, Simpa Salami highlights a new urine-based test for detecting aggressive prostate cancer, which promises improvement upon current biomarker tests. It's been estimated that prostate cancer often occurs in multiple areas of the prostate in about 60% to 80% of patients. Prostate biopsy is the strategy for detecting aggressive prostate cancer based upon elevated...
|
